Oestrogen receptor β: What it means for patients with breast cancer
Speirs V., Carder PJ., Lane S., Dodwell D., Lansdown MRJ., Hanby AM.
Oestrogen receptor (ER) α is a well established prognostic marker in breast cancer, and all patients who are ERα positive receive tamoxifen as adjuvant endocrine therapy. Although ERα predicts a favourable disease outcome, the usefulness of ERβ as a clinical prognostic marker remains to be defined. Here, we outline the history of both ERs and discuss the implications ERβ has to patients with breast cancer.